Who is sponsoring NCT03671174?

NCT03671174 is sponsored by RenJi Hospital.

What condition does NCT03671174 study?

NCT03671174 studies Undifferentiated Connective Tissue Disease, Recurrent Pregnancy Loss.

What drugs are being tested in NCT03671174?

Interventions: Prednisone, Hydroxychloroquine, Aspirin, low molecular weight heparin.

What is the status of NCT03671174?

NCT03671174 is currently UNKNOWN.

Last reviewed 2019-08-08 · How we verify

A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtuses (ILIFE) Trial

NCT03671174 NA UNKNOWN

Undifferentiated connective tissue diseases (UCTD) are known to increase the risk of pregnancy morbidities, including recurrent pregnancy loss. However, there is no consensus or guideline about the treatment for recurrent pregnancy loss in UCTD patients. Therefore, based on the tendency to thrombosis formation and placental inflammation in the pathogenesis of UCTD, this trial proposes to evaluate the effect of hydroxychloroquine with or without prednisone combined with anticoagulation on pregnancy outcomes in recurrent pregnancy loss patients with UCTD.

Details

Lead sponsor	RenJi Hospital
Phase	NA
Status	UNKNOWN
Enrolment	420
Start date	2019-08-02
Completion	2023-02

Conditions

Undifferentiated Connective Tissue Disease
Recurrent Pregnancy Loss

Interventions

Prednisone
Hydroxychloroquine
Aspirin
low molecular weight heparin

Primary outcomes

Live birth rate — After 28 weeks of gestation
Percentage of all cycles that lead to live birth

Countries

China